The class of SUV39H2 activators encompasses a diverse array of chemicals with intricate regulatory roles in modulating the activity of the SUV39H2 protein, a histone methyltransferase involved in chromatin remodeling and gene expression. These activators exert their influence through various direct and indirect mechanisms, collectively highlighting the complex regulatory networks governing SUV39H2 activation. Direct activators, such as Chaetocin, UNC0646, and A-196, specifically target SUV39H2's methyltransferase activity, disrupting the methylation of histone H3 at lysine 9 (H3K9). This targeted inhibition leads to alterations in chromatin structure and gene expression patterns associated with SUV39H2-mediated processes. Additionally, compounds like BIX 01294 and EPZ-5676 indirectly influence SUV39H2 by targeting other histone methyltransferases, affecting the broader epigenetic landscape and modulating SUV39H2 expression and function.
Indirect activators, such as SGC-CBP30 and GSK126, disrupt the interaction between histone acetyltransferases and acetylated histones, influencing the epigenetic landscape and potentially leading to changes in SUV39H2-mediated processes through alterations in histone acetylation and methylation dynamics. The diverse mechanisms employed by SUV39H2 activators underscore the intricate regulation of SUV39H2 and provide valuable insights into potential strategies for manipulating its activity in various cellular contexts. Understanding the specific pathways influenced by these compounds enhances our grasp of the complex networks governing SUV39H2 activation, paving the way for targeted interventions in conditions where SUV39H2 function is pivotal.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
A-196 | 1982372-88-2 | sc-507414 | 1 mg | $72.00 | ||
A-196 is a potent and selective inhibitor of SUV39H1 and SUV39H2, targeting their methyltransferase activity. This small molecule interferes with the methylation of histone H3 at lysine 9, impacting chromatin structure and gene expression. The inhibition of SUV39H2 by A-196 contributes to the modulation of specific cellular processes influenced by H3K9 methylation. | ||||||
9-[5-Deoxy-5-[[cis-3-[2-[6-(1,1-dimethylethyl)-1H-benzimidazol-2-yl]ethyl]cyclobutyl](1-methylethyl)amino]-β-D-ribofuranosyl]-9H-purin-6-amine | 1380288-87-8 | sc-500607 | 50 mg | $13500.00 | ||
This compound, also called EPZ-5676, is a small molecule inhibitor targeting DOT1L methyltransferase, indirectly impacting SUV39H2 activity. By modulating the methylation of histone H3 at lysine 79, EPZ-5676 can influence the overall chromatin landscape, potentially leading to changes in SUV39H2 expression and function. | ||||||
SGC-CBP30 | 1613695-14-9 | sc-473871 sc-473871A | 5 mg 10 mg | $178.00 $338.00 | ||
SGC-CBP30 is a potent and selective inhibitor of the CREB-binding protein (CBP)/p300 bromodomain, indirectly influencing SUV39H2 activity. By disrupting the interaction between CBP/p300 and acetylated histones, SGC-CBP30 can impact the epigenetic landscape and gene expression patterns, potentially leading to changes in SUV39H2-mediated processes through alterations in histone acetylation and methylation dynamics. | ||||||
GSK126 | 1346574-57-9 | sc-490133 sc-490133A sc-490133B | 1 mg 5 mg 10 mg | $90.00 $238.00 $300.00 | ||
GSK126 is a selective inhibitor of EZH2, a histone methyltransferase involved in the trimethylation of histone H3 lysine 27 (H3K27). The indirect impact of GSK126 on SUV39H2 arises from its modulation of the broader histone methylation landscape, influencing chromatin structure and gene expression. | ||||||
Sinefungin | 58944-73-3 | sc-203263 sc-203263B sc-203263C sc-203263A | 1 mg 100 mg 1 g 10 mg | $266.00 $5100.00 $39576.00 $690.00 | 4 | |
Sinefungin is a natural product that serves as a universal methyl group donor, indirectly impacting SUV39H2 activity. By providing methyl groups for histone methyltransferases, including SUV39H2, Sinefungin influences the overall histone methylation landscape. |